SAN

72.905

-0.65%↓

SRT3

218.55

-2.39%↓

ORNBV.FI

68.65

+0.22%↑

PHMA

95.6

-1.49%↓

DRW3

90.75

-0.33%↓

SAN

72.905

-0.65%↓

SRT3

218.55

-2.39%↓

ORNBV.FI

68.65

+0.22%↑

PHMA

95.6

-1.49%↓

DRW3

90.75

-0.33%↓

SAN

72.905

-0.65%↓

SRT3

218.55

-2.39%↓

ORNBV.FI

68.65

+0.22%↑

PHMA

95.6

-1.49%↓

DRW3

90.75

-0.33%↓

SAN

72.905

-0.65%↓

SRT3

218.55

-2.39%↓

ORNBV.FI

68.65

+0.22%↑

PHMA

95.6

-1.49%↓

DRW3

90.75

-0.33%↓

SAN

72.905

-0.65%↓

SRT3

218.55

-2.39%↓

ORNBV.FI

68.65

+0.22%↑

PHMA

95.6

-1.49%↓

DRW3

90.75

-0.33%↓

Home・Aktien・Vetoquinol SA

Vetoquinol SA

Open

BrancheGesundheitswesen

77.1 1.31

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

76.5

Max

77.1

Schlüsselkennzahlen
By Trading Economics
Einkommen	25M
Verkäufe	10M 268M
KGV Branchendurchschnitt	14.588 49.8
Dividendenrendite	1.21
Gewinnspanne	9.734
Angestellte	2,497
EBITDA	252M 301M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+44.55% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	1.21% 2.25%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-57M 878M
Vorheriger Eröffnungskurs	75.79
Vorheriger Schlusskurs	77.1

Nachrichtenstimmung

By Acuity

50%

166 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

72.6 / 75.1 Unterstützung & Widerstand

Vetoquinol SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 23:58 UTC

Ergebnisse

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. Mai 2026, 22:57 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. Mai 2026, 23:52 UTC

Ergebnisse

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. Mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. Mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. Mai 2026, 23:11 UTC

Ergebnisse

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. Mai 2026, 23:06 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. Mai 2026, 23:05 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. Mai 2026, 23:04 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. Mai 2026, 23:02 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. Mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. Mai 2026, 22:42 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. Mai 2026, 22:33 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. Mai 2026, 22:32 UTC

Ergebnisse

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie: 68% of FY Income From International >MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. Mai 2026, 22:29 UTC

Ergebnisse

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. Mai 2026, 22:26 UTC

Ergebnisse

Macquarie to End Share Buyback Extended in November>MQG.AU

7. Mai 2026, 22:25 UTC

Ergebnisse

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer-Vergleich

Kursveränderung

Vetoquinol SA Prognose

Kursziel

By TipRanks

44.55% Vorteil

12-Monats-Prognose

Durchschnitt 110 EUR 44.55%

Hoch 110 EUR

Tief 110 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vetoquinol SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vetoquinol SA – Dist abgegeben haben.

Technischer Score

By Trading Central

72.6 / 75.1Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

166 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.